A Multi-Practice Quality Initiative Evaluating Antiemetic Use in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan-nxki (T-DXd)

Stephan Rosenfeld, MD[1]; Vikram Gorantla, MD[3]; Iuliana Shapira, MD[4]; Anna Rui, MPH[2]; Ashley Lamb, MBA[2]; Dawn Brenneman, MS[2]; Brandon Wang, MBA[2]; Lisa Morere, RN, MSN, ANP[2]; Mike Gart, MBA[2]; Rushir Choski, MD[3]; Prateesh Varughese, PharmD[2]; Robert Geller, MD[2]
[1]Highlands Oncology Group, Fayetteville, AR, USA; [2]Integra Connect PrecisionQ, West Palm Beach, FL, USA; [3]UPMC, Pittsburgh, PA, USA; [4]Regional Cancer Care Associates, Teaneck, NJ, USA

SAN ANTONIO BREAST CANCER SYMPOSIUM®
DECEMBER 10–13, 2024
SABCS.ORG


Background

- In January 2023, the National Comprehensive Cancer Network (NCCN) updated its guidelines to recommend the use of 5HT3, NK1, dexamethasone (Dex), and olanzapine (O) for patients receiving highly emetogenic regimens, such as fam-trastuzumab deruxtecan-nxki (T-DXd). Notably, the package insert for T-DXd did not classify it as highly emetogenic until April 2024.
- An Integra PrecisionQ multi-practice quality initiative was conducted with Highlands Oncology Group (HOG), University of Pittsburgh Medical Center (UPMC), and Regional Cancer Care Associates (RCCA) to assess adherence to recommended antiemetic use in patients with metastatic breast cancer receiving T-DXd. This initiative compared current practices to NCCN guidelines, identified potential gaps in care, and implemented strategies to address these gaps.
- Our goal is to demonstrate improvements in antiemetic utilization for metastatic breast cancer patients treated with T-DXd as a result of this quality initiative.

Methods

- Using the Integra PrecisionQ de-identified database, HER2+ and HER2low patients treated with T-DXd were evaluated for specific time periods at each practice related to antiemetics utilization.
  - HOG (Baseline: 1/1/2022-12/31/2023; follow-up: 01/01/2024-06/04/2025)
  - UPMC (Baseline: 1/1/2022-04/30/2024; follow-up: 05/01/2024-06/04/2025)
  - RCCA (Baseline: 1/1/2022-01/01/2024; follow-up: 02/01/2024-06/04/2025)
- For the baseline period, we completed a retrospective analysis of the antiemetic utilization within their HER2+ and HER2low patient cohorts. The results of the initial baseline analysis were shared with practice leaders and oncologists at the practices. The practices updated their antiemetic order sets, and we evaluated the order set changes during the follow-up period to account for any improvement in antiemetic utilization. Data are presented using descriptive statistics.

Figure 1: Utilization of Anti Emetics by Practice



Results

- The total patients evaluated in the initiative were:
  - HOG: Baseline (49 pts), Follow-up (27 pts)
  - UPMC: Baseline (212 pts), Follow-up (110 pts)
  - RCCA: Baseline (132 pts), Follow-up (99 pts).
- In the follow-up analysis, utilization of the recommended combinations of antiemetics, 5HT3+NK1+O+/-DEX, and 5HT3+NK1+/-DEX, increased from:
  - 47% to 85% at RCCA
  - 29% to 100% at UPMC
  - 49% to 100% at HOG
- Overall rate increased from 37% to 94%.

Conclusion

- **This multi-practice quality initiative led to improved antiemetic utilization that is in line with NCCN guidelines in HER2+ and HER2low metastatic breast cancer patients treated with T-DXd.**
- **These findings highlight that, even after guidelines have been established for some time, oncology practices can benefit from regularly evaluating their own data to assess their treatment compared to the latest clinical standards.**

Contact

Dr. Stephen Rosenfeld, MD
Highlands Oncology Group
Email: ssrosenfeld@msn.com

This presentation is the intellectual property of the author/presenter. Contact Cecelia Wall at cecelia.wall@integraconnect.com for permission to reprint and/or distribute.

© Poster Template by Genigraphics® 1.800.790.4001 www.genigraphics.com